225 related articles for article (PubMed ID: 38194023)
1. Exploring the Cost Effectiveness of a Whole-Genome Sequencing-Based Biomarker for Treatment Selection in Patients with Advanced Lung Cancer Ineligible for Targeted Therapy.
Mfumbilwa ZA; Simons MJHG; Ramaekers B; Retèl VP; Mankor JM; Groen HJM; Aerts JGJV; Joore M; Wilschut JA; Coupé VMH
Pharmacoeconomics; 2024 Apr; 42(4):419-434. PubMed ID: 38194023
[TBL] [Abstract][Full Text] [Related]
2. Association of Survival and Immune-Related Biomarkers With Immunotherapy in Patients With Non-Small Cell Lung Cancer: A Meta-analysis and Individual Patient-Level Analysis.
Yu Y; Zeng D; Ou Q; Liu S; Li A; Chen Y; Lin D; Gao Q; Zhou H; Liao W; Yao H
JAMA Netw Open; 2019 Jul; 2(7):e196879. PubMed ID: 31290993
[TBL] [Abstract][Full Text] [Related]
3. Cost-Effectiveness Analysis of Atezolizumab versus Platinum-Based Chemotherapy as First-Line Treatment for Patients with Unresectable Advanced Non-small Cell Lung Cancer with PD-L1 Expression Status in Japan.
Chisaki Y; Nakano H; Minamide J; Yano Y
Clin Drug Investig; 2023 Nov; 43(11):839-850. PubMed ID: 37891362
[TBL] [Abstract][Full Text] [Related]
4. Early Cost Effectiveness of Whole-Genome Sequencing as a Clinical Diagnostic Test for Patients with Inoperable Stage IIIB,C/IV Non-squamous Non-small-Cell Lung Cancer.
Simons MJHG; Retèl VP; Ramaekers BLT; Butter R; Mankor JM; Paats MS; Aerts JGJV; Mfumbilwa ZA; Roepman P; Coupé VMH; Uyl-de Groot CA; van Harten WH; Joore MA
Pharmacoeconomics; 2021 Dec; 39(12):1429-1442. PubMed ID: 34405371
[TBL] [Abstract][Full Text] [Related]
5. Cost-Effectiveness Analysis of Sintilimab Plus Chemotherapy in Advanced Non-Squamous Non-Small Cell Lung Cancer: A Societal Perspective.
Li F; Chen Y; Xiao D; Jiang S; Yang Y
Adv Ther; 2024 Apr; 41(4):1436-1449. PubMed ID: 38356107
[TBL] [Abstract][Full Text] [Related]
6. Immunotherapy Guided by Immunohistochemistry PD-L1 Testing for Patients with NSCLC: A Microsimulation Model-Based Effectiveness and Cost-Effectiveness Analysis.
Rui M; Wang Y; Li Y; Fei Z
BioDrugs; 2024 Jan; 38(1):157-170. PubMed ID: 37792142
[TBL] [Abstract][Full Text] [Related]
7. Integration of comprehensive genomic profiling, tumor mutational burden, and PD-L1 expression to identify novel biomarkers of immunotherapy in non-small cell lung cancer.
Shi Y; Lei Y; Liu L; Zhang S; Wang W; Zhao J; Zhao S; Dong X; Yao M; Wang K; Zhou Q
Cancer Med; 2021 Apr; 10(7):2216-2231. PubMed ID: 33655698
[TBL] [Abstract][Full Text] [Related]
8. Cost-effectiveness analysis of serplulimab plus chemotherapy in the first-line treatment for PD-L1-positive esophageal squamous cell carcinoma in China.
Liu S; Jiang N; Dou L; Li S
Front Immunol; 2023; 14():1172242. PubMed ID: 37215110
[TBL] [Abstract][Full Text] [Related]
9. Cost-effectiveness analysis of pembrolizumab plus chemotherapy with PD-L1 test for the first-line treatment of NSCLC.
Wan N; Zhang TT; Hua SH; Lu ZL; Ji B; Li LX; Lu LQ; Huang WJ; Jiang J; Li J
Cancer Med; 2020 Mar; 9(5):1683-1693. PubMed ID: 31945265
[TBL] [Abstract][Full Text] [Related]
10. Cost-effectiveness of sintilimab plus chemotherapy versus chemotherapy alone as first-line treatment of locally advanced or metastatic oesophageal squamous cell carcinoma.
Liu L; Wang L; Chen L; Ding Y; Zhang Q; Shu Y
Front Immunol; 2023; 14():1092385. PubMed ID: 36756110
[TBL] [Abstract][Full Text] [Related]
11. The effect of PD-L1 categories-directed pembrolizumab plus chemotherapy for newly diagnosed metastatic non-small-cell lung cancer: a cost-effectiveness analysis.
Wu B; Lu S
Transl Lung Cancer Res; 2020 Oct; 9(5):1770-1784. PubMed ID: 33209600
[TBL] [Abstract][Full Text] [Related]
12. Cost-effectiveness analysis of pembrolizumab versus standard-of-care chemotherapy for first-line treatment of PD-L1 positive (>50%) metastatic squamous and non-squamous non-small cell lung cancer in France.
Chouaid C; Bensimon L; Clay E; Millier A; Levy-Bachelot L; Huang M; Levy P
Lung Cancer; 2019 Jan; 127():44-52. PubMed ID: 30642550
[TBL] [Abstract][Full Text] [Related]
13. Combining Genomic Biomarkers to Guide Immunotherapy in Non-Small Cell Lung Cancer.
van de Haar J; Mankor JM; Hummelink K; Monkhorst K; Smit EF; Wessels LFA; Cuppen E; Aerts JGJV; Voest EE
Clin Cancer Res; 2024 Apr; 30(7):1307-1318. PubMed ID: 38300729
[TBL] [Abstract][Full Text] [Related]
14. Comparative cost-effectiveness of first-line pembrolizumab plus chemotherapy vs. chemotherapy alone in persistent, recurrent, or metastatic cervical cancer.
Lin YT; Wang C; He XY; Yao QM; Chen J
Front Immunol; 2023; 14():1345942. PubMed ID: 38274823
[TBL] [Abstract][Full Text] [Related]
15. Economic Evaluation of First-Line Camrelizumab for Advanced Non-small-cell Lung Cancer in China.
Xiang G; Gu L; Chen X; Wang F; Chen B; Zhao J; Lu Y; Chang F; Zhu Y
Front Public Health; 2021; 9():743558. PubMed ID: 34957008
[No Abstract] [Full Text] [Related]
16. Predictive values of genomic variation, tumor mutational burden, and PD-L1 expression in advanced lung squamous cell carcinoma treated with immunotherapy.
Xu Y; Li H; Huang Z; Chen K; Yu X; Sheng J; Zhang HH; Fan Y
Transl Lung Cancer Res; 2020 Dec; 9(6):2367-2379. PubMed ID: 33489799
[TBL] [Abstract][Full Text] [Related]
17. Cost-Effectiveness Analysis of Nivolumab Plus Ipilimumab vs. Chemotherapy as First-Line Therapy in Advanced Non-Small Cell Lung Cancer.
Hu H; She L; Liao M; Shi Y; Yao L; Ding D; Zhu Y; Zeng S; Carbone DP; Huang J
Front Oncol; 2020; 10():1649. PubMed ID: 33014826
[No Abstract] [Full Text] [Related]
18. The cost-effectiveness of including liquid biopsy into molecular profiling strategies for newly diagnosed advanced non-squamous non-small cell lung cancer in an Asian population.
Liu S; Graves N; Tan AC
Lung Cancer; 2024 May; 191():107794. PubMed ID: 38636314
[TBL] [Abstract][Full Text] [Related]
19. Cost-Effectiveness of Avelumab Maintenance Therapy for Advanced or Metastatic Urothelial Carcinoma in the United States.
Peng Y; She Z; Peng L; Liu Q; Yi L; Luo X; Li S; Wang L; Qin S; Wan X; Tan C
Adv Ther; 2021 Dec; 38(12):5710-5720. PubMed ID: 34693504
[TBL] [Abstract][Full Text] [Related]
20. Cost-effectiveness of first-line immunotherapies for advanced non-small cell lung cancer.
Yang SC; Ou HT; Su WC; Wang SY
Cancer Med; 2023 Apr; 12(7):8838-8850. PubMed ID: 36653947
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]